Boston, MA, United States of America

Eirini Iliaki

This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Massachusetts Eye and Ear Infirmary. Active years: 2008-2017.

USPTO Granted Patents = 3 

% Patents Active = 33.3

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2008-2017

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Eirini Iliaki: Innovator in Ocular Disorder Treatments

Introduction

Eirini Iliaki is a prominent inventor based in Boston, MA (US). She has made significant contributions to the field of ocular medicine, particularly in the treatment of intraocular disorders. With a total of 3 patents to her name, her work is paving the way for innovative therapies in this critical area of healthcare.

Latest Patents

Among her latest patents, Eirini has developed a method for treating ocular disorders. This invention involves administering a Very Late Antigen-4 (VLA-4) antagonist to mammals for the treatment of selected ocular disorders. This groundbreaking approach has the potential to improve the quality of life for many patients suffering from these conditions.

Career Highlights

Eirini Iliaki is affiliated with the Massachusetts Eye and Ear Infirmary, where she continues her research and development in ocular treatments. Her dedication to advancing medical science is evident in her innovative approaches and the impact of her work on patient care.

Collaborations

Eirini collaborates with esteemed colleagues such as Joan W. Miller and Anthony P. Adamis. These partnerships enhance her research efforts and contribute to the advancement of ocular health.

Conclusion

Eirini Iliaki is a trailblazer in the field of ocular disorder treatments, with her innovative patents and collaborations driving progress in medical science. Her work exemplifies the importance of innovation in improving patient outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…